ANALYTICAL/QUALITY ARTICLES
-
![GettyImages-2263603976]( "Personalized mRNA Cancer Immunotherapies: Closing The Biological Knowledge Gap")
Personalized mRNA Cancer Immunotherapies: Closing The Biological Knowledge Gapit was a great honor to take Advancing RNA on the road to London to CPI’s/BIA’s/Imperial College London’s RNA Vaccines & Therapeutics Conference to moderate a discussion on personalized cancer immunotherapies. In the following two-part article, I’ll share the advancements needed in two areas — biological knowledge and manufacturing — to ensure we’re capable of meeting patients’ needs in the personalized sector.
-
![Future-GettyImages-834713748]( "Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions")
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future DirectionsThis last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
![PCR DNA sequence analysis-GettyImages-942229746]( "Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control")
Antibody–Oligonucleotide Conjugates, Part 3: Analytical ControlLet's delve into analytical control strategy, OAR/DAR measurement, bioanalytical characterization, stability and formulation, and more.
-
![high risky goals-GettyImages-1357255862]( "Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan")
Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development PlanThe emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.
-
![GettyImages-2219636387]( "Can Engineering The Passenger Strand Improve siRNA Performance?")
Can Engineering The Passenger Strand Improve siRNA Performance?How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it?
-
![Measuring Success GettyImages-1319232417]( "How Should We Measure The True Potency Of RNA Therapeutics?")
How Should We Measure The True Potency Of RNA Therapeutics?An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.
ANALYTICAL/QUALITY VIDEOS
Recombinant Factor C testing offers a pharmacopeia-recognized, animal-free alternative to LAL with fewer interference risks, but regulatory hesitation slows adoption across the industry.
As both Advancing RNA Live speakers point out in this segment, the MHRA guidance focuses deeply on the critical role bioinformatics and AI/ML approaches will play in the development of personalized immunotherapies. Here, Eliquent Life Sciences’ Tiffany Lucas and CureVac’s Ulrike Jägle address the biggest challenges they anticipate companies will face in meeting the agencies’ recommendations.
Advancing RNA Live panelists Venkat Krishnamurthy, April Sena, and Max De Long share their perspectives on the most important regulatory considerations for gRNA production utilizing an enzymatic ligation approach.
We all know that plasmid quality is foundational in dictating the quality of the final mRNA drug substance. In this clip homing in on upstream process considerations, speakers Stu Sundseth (Tune Therapeutics), Marc Wolfgang (Sail Biomedicines), and Christian Dohmen (Ethris) outline some of the most important CQAs for plasmids and the impact they can have on the resulting quality of the mRNA drug substance for linear mRNA.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![iStock-954300680-gene-therapy-dna]( "RNA Biotherapeutics — A New Approach To An Old Problem")
RNA Biotherapeutics — A New Approach To An Old ProblemCheck out a brief history of RNA-based therapy and how Droplet Digital™ PCR supports this field of work.
-
![iStock-1208824917-molecule-structure]( "Metabolite ID And Relative Quantification Of Oligonucleotides In Plasma")
Metabolite ID And Relative Quantification Of Oligonucleotides In PlasmaThis technical note describes the identification, relative quantification, and structural confirmation of the chain-shortened metabolites of a phosphorothioated oligonucleotide.
-
![RNA abbreviation of ribonucleic acid-GettyImages-1453953422]( "Exploring Osmolality As A CQA Within RNA Therapeutics")
Exploring Osmolality As A CQA Within RNA TherapeuticsDiscover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.
-
![GettyImages-624034258 chemical mixing]( "Demystifying CRISPR gRNA Chemical Modifications")
Demystifying CRISPR gRNA Chemical ModificationsChemical modifications on CRISPR gRNAs enhance stability, editing efficiency, and reduce immune responses, enabling in vivo applications and clinical success.
-
![Feature Image 1]( "mRNA Product Purification Process Strategies")
mRNA Product Purification Process StrategiesImpurities from IVT can induce undesired immune responses and negatively impact translation efficiency. Explore the pros and cons of each option for mRNA purification.
-
![GettyImages-2160715091 lab analysis]( "Targeted LC-MS/MS Detection Of Lipid Impurities In Lipid Nanoparticles")
Targeted LC-MS/MS Detection Of Lipid Impurities In Lipid NanoparticlesLearn about an HPLC-MS/MS method for detecting lipid impurities in lipid nanoparticles (LNPs) and why it is critical for quality control of LNP-based drug delivery systems.
-
![Primrose Bio - Advancing RNA_Prima case study (002)]( "How Polymerase Selection Shapes IVT Outcomes: Insights From An Independent Evaluation")
How Polymerase Selection Shapes IVT Outcomes: Insights From An Independent EvaluationdsRNA contamination starts with polymerase choice. See how engineered RNA polymerases cut dsRNA by more than 10x compared to wild-type T7 in independent IVT testing.
